US equities |
SPCX $166.85 ▲+4.97% NVDA $236.89 ▲+1.26% MU $1,064.53 ▼-0.96% TSLA $377.42 ▲+1.84% MSFT $526.35 ▲+1.70% SNDK $1,713.92 ▼-0.35% INTC $117.22 ▼-1.77% META $745.33 ▲+2.37%
FinancialContent

Bristol-Myers Squibb (NY:BMY)

58.81 -2.34 (-3.83%)
Delayed Quote Updated: 11:52 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
93 94 Next >
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
What's going on in today's session: S&P500 movers ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ ↗
Bristol Myers’ ADEPT-2 update drew support from JPMorgan and William Blair following the decision to continue the study with added enrollment. 
Via Stocktwits
News headline image
These S&P500 stocks are moving in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
From Bristol Myers Squibb
Via Business Wire
News headline image
Amazon Unleashes AI Frontier Agents: A New Era of Autonomous Digital Workers
Amazon (NASDAQ: AMZN) has unveiled a groundbreaking class of AI agents, dubbed "frontier agents," capable of operating autonomously for extended periods—even days—without constant human intervention.... 
Via TokenRing AI
Topics Artificial Intelligence Economy
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
News headline image
Bristol-Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case ↗
Bristol-Myers Squibb (BMY) presents a value investment case, trading at a deep discount with strong earnings power and a high dividend amid near-term challenges. 
Via Chartmill
News headline image
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever ↗
If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Dividend Stocks to Buy and Hold ↗
Patience will be rewarded for those who stick with these two healthcare stocks. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend? ↗
The pharma stock yields more than 4x the S&P 500 average. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Bristol-Myers (BMY) Earnings Call Transcript ↗
Bristol-Myers (BMY) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a Compelling Mix of High Yield and Financial Strength for Dividend Investors ↗
Bristol-Myers Squibb (BMY) offers a strong 5.4% dividend yield, backed by a history of reliable payments, robust profitability, and a sound financial position for income investors. 
Via Chartmill
News headline image
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies... 
Via StockStory
Topics Economy
News headline image
Monday's session: gap up and gap down stock in the S&P500 index ↗
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Bristol Myers Squibb to Host Hematology-Focused Investor Event
From Bristol Myers Squibb
Via Business Wire
News headline image
What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? ↗
 
Via Benzinga
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses
The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
From Bristol Myers Squibb
Via Business Wire
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
93 94 Next >